Roivant reports top-line data from IMVT-1402 CLE trial

Roivant has announced top-line results from the first period of a proof-of-concept clinical study evaluating IMVT-1402 to treat CLE. This study enrolled 57 adult patients with CLE, who were assigned to receive either IMVT-1402 or a placebo. The study enrolled 57 adult patients with CLE, who were assigned to receive either IMVT-1402 or a placebo. Credit: Stock-Asso / Shutterstock.com. Roivant has announced top-line results from the first period of a proof-of-concept clinical study evaluating IMVT-1402, a monoclonal antibody also known as imeroprubart, to treat cutaneous lupus erythematosus (CLE). The randomised, double-blind, placebo-controlled trial, conducted by Immunovant, a majority-owned subsidiary of…

Source: Clinical Trials Arena